Contrasting CannLabs (OTCMKTS:CANL) and Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC) and CannLabs (OTCMKTS:CANL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Risk and Volatility

Celcuity has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, CannLabs has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

63.3% of Celcuity shares are owned by institutional investors. 15.8% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Celcuity and CannLabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-62.66%	-39.78%
CannLabs	N/A	N/A	N/A

Earnings & Valuation

This table compares Celcuity and CannLabs”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$63.78 million	($2.61)	-5.22
CannLabs	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Celcuity and CannLabs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0	0	6	1	3.14
CannLabs	0	0	0	0	0.00

Celcuity presently has a consensus price target of $29.17, indicating a potential upside of 114.15%. Given Celcuity’s stronger consensus rating and higher possible upside, research analysts plainly believe Celcuity is more favorable than CannLabs.

Summary

Celcuity beats CannLabs on 6 of the 9 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About CannLabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.